Email Updates

You are here

Home»Trial Summary Table

Trial Summary Table

Trial Name Phase Start Date Sponsors Countries Population Candidate(s) Status Expected Completion Date
90-day Pod-type Etonogestrel/Ethinyl Estradiol/QGriffithsin (QGRFT) Intravaginal Ring [EEQ IVR] Pre-clinical Tuesday, April 7, 2020 NIAID Q-GRFT Ongoing March 2025
A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04 I Monday, November 11, 2013 CONRAD United States of America Women 1% tenofovir gel, HEC gel, tenofovir Completed January 2015
Amphora/QGriffithsin (QGRFT) fast-dissolving vaginal insert (FDI) Pre-clinical Monday, May 24, 2021 NIAID Q-GRFT May 2021
Cabotegravir implant (Preclinical) Pre-clinical NIAID United States of America Men Cabotegravir (GSK 744) Completed
CAPRISA 004 IIb Tuesday, May 1, 2007 Centre for the AIDS Programme of Research in South Africa; FHI 360; United States Agency for International Development (USAID); CONRAD South Africa Women 1% tenofovir gel Completed March 2010
CAPRISA 008 III, II Wednesday, October 31, 2012 Centre for the AIDS Programme of Research in South Africa, CONRAD, Gilead Sciences, FHI 360, Institute for Health Care Improvement South Africa Women 1% tenofovir gel Completed December 2015
CLIP Ring Pre-clinical Sunday, December 1, 2019 CDC, NIAID Men Islatravir (MK-8591) November 2024
Comparison of Tenofovir Vaginal Gel and Film Formulations (FAME-05) Open Label Tuesday, November 11, 2014 CONRAD Women 1% tenofovir gel, tenofovir Completed December 1015
CONRAD 117 I Thursday, February 28, 2013 CONRAD United States of America Women 1% tenofovir gel, FTC, TVF/FTC Completed January 2014
CONRAD 118 I Tuesday, December 31, 2013 CONRAD United States of America Women 1% tenofovir gel, Contraceptive Vaginal Ring, Metronidazole, Terconazole Completed December 2014

Pages